OncoTalks | Oncology Insights at Your Fingertips

Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Pelster discusses the biology behind DLL3 overexpression and the latest clinical data on DLL3‑directed therapies, including bispecific T‑cell engagers. This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

With limited durable options available, new approaches are urgently needed in EP-NEC. This episode highlights emerging therapies, including immunotherapy‑based strategies and early clinical trial data shaping future treatment directions. This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Explore the current EP‑NEC treatment landscape, from first‑line platinum‑based therapy and etoposide to second‑line challenges. Dr. Pelster reviews guideline‑recommended options, sequencing considerations, and why clinical trials are essential in this aggressive disease. This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Meredith Pelster introduces extrapulmonary neuroendocrine carcinoma (EP‑NEC), outlining how patients present and what distinguishes this rare disease. Learn the key elements of diagnostic workup, including pathology, imaging, and features that differentiate EP‑NEC from other neuroendocrine tumors. This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, host Tulsi Patel speaks with Brandon Dyson, PharmD, BCOP, BCPS, Director of Pharmacy Education at Texas Oncology, about how the Maximum Fair Price (MFP) program may influence prostate cancer care in community oncology. They review therapies selected for MFP regulation, key implementation timelines, and share practical steps oncology providers and practices can take now to prepare. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, host Tulsi Patel speaks with Dr. Hope Rugo about the evolving role of antibody‑drug conjugates (ADCs) in breast cancer, with a focus on sacituzumab govitecan, the first and currently only approved ADC for patients with previously treated metastatic triple‑negative breast cancer (mTNBC). Dr. Rugo highlights key clinical data supporting its approvals in mTNBC and HR‑positive/HER2‑negative disease, and discusses indications, efficacy, safety considerations, and emerging first‑line trial findings that may influence future treatment sequencing. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, host Dr. Ira Zackon is joined by Dr. Alexander Spira to discuss comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They unpack key findings from a recent study revealing variability in testing practices and emphasize the importance of comprehensive DNA- and RNA-based next-generation sequencing over single-gene testing. Tune in to review the latest clinical guidelines, learn how testing impacts treatment sequencing, and glean insights into how community oncology practices can overcome barriers to ensure that all NSCLC patients receive guideline-concordant testing and treatment.   Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In the final episode of this four-part series, Dr. Mohit Narang looks ahead to emerging innovations in multiple myeloma. Learn about new therapeutic targets, MRD testing, sequencing strategies, and personalized approaches that aim to optimize outcomes and bring us closer to functional cures. This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In part three of four, Dr. Mohit Narang explores how bispecific antibodies and other advanced treatments are being implemented in real-world community oncology practices. Discover the operational challenges, safety considerations, and strategies that enable community oncology centers to expand access to these transformative therapies for the broader patient population. This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In part two of four, Dr. Mohit Narang examines the rapidly evolving treatment landscape for multiple myeloma. Tune in to learn how therapy has progressed from doublets to quadruplets, reshaping the role of autologous stem cell transplant, and the impact of the latest immune therapies, including monoclonal antibodies, bispecific antibody therapy, and CAR-T approaches. This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In part one of four, Dr. Mohit Narang from Maryland Oncology Hematology provides a foundational overview of multiple myeloma.  Tune in to learn how its incidence has evolved over the past thirty years, what we know today about disease risk factors, and the molecular mechanisms underlying multiple myeloma pathophysiology and diagnosis.  This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this OncoTalks Case Journey, Dr. Paul Conkling discusses the importance of comprehensive genomic profiling and targeted therapy in non-small cell lung cancer (NSCLC).  Through the lens of two NSCLC patients who received contrasting testing and treatment, listeners learn about the actionable oncogenic biomarker ROS1, which personalized testing methods are most effective for diagnosing ROS1 variants, and the latest advancements in ROS1-targeted therapy. These cases underscore the importance of aligning therapeutic approaches with evidence-based strategies and clinical guidelines by illustrating their direct impact on patient outcomes. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Live from McKesson Accelerate 2025, Dr. Ira Zackon sits down with Dr. Martin Dietrich to discuss the latest in ROS1+ non-small cell lung cancer. They explore the rarity and significance of ROS1 mutations and clinical presentation. The conversation highlights evolving treatment strategies – from first-generation TKIs to next-generation options – plus safety profiles, resistance mechanisms, and NCCN guideline recommendations. Tune in for practical insights on optimizing therapy and improving outcomes for patients with ROS1+ NSCLC. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Live from McKesson Accelerate 2025, host Suzzette Arnal talks with Dr. Melissa Johnson about how precision medicine is reshaping care for non-small cell lung cancer patients. They cover comprehensive biomarker testing, the role of DNA and RNA-based NGS, and why patient characteristics matter. Dr. Johnson also highlights breakthroughs in targeted therapies, emerging immunotherapies, and the critical role of clinical trials in improving outcomes. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, Dr. Paul Conkling and Dr. Eric Nadler take a deep dive into the IMforte trial—a pivotal phase III global study evaluating lurbinectedin and atezolizumab as a first-line maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC). They unpack the trial’s design and results, highlighting key safety and efficacy data that led to the FDA’s approval of this combination regimen on October 2, 2025. Tune in to hear expert perspectives on how this new indication will influence clinical practice and improve outcomes for ES-SCLC patients. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode, Dr. Paul Conkling and Dr. David Spetzler explore the advantages of broad molecular profiling over smaller panels, emphasizing its superior accuracy in detecting critical biomarkers and identifying eligibility for emerging therapies. They discuss how AI is transforming treatment sequencing and improving patient outcomes, while also highlighting key technical factors—such as microdissection and advanced extraction methods—that enhance the precision of both tissue and liquid biopsies. Dr. Spetzler further addresses the importance of high assay coverage and the role of whole exome and transcriptome sequencing in delivering comprehensive diagnostic insights, along with the challenges of clinical validation and regulatory approval. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, Dr. Paul Conkling and Dr. Kashif Ali explore how minimal residual disease (MRD) testing using circulating tumor DNA (ctDNA) is reshaping breast cancer management. They discuss how this innovative approach enables the detection of molecular disease that may persist after treatment — often before clinical or radiographic signs appear. Research shows MRD testing can identify recurrence months earlier than conventional methods, allowing for timely intervention and more informed decision-making. As a result, MRD testing is becoming an increasingly valuable tool in personalized cancer care. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, Dr. Ira Zackon, Senior Medical Director at Ontada, is joined by Dr. Marcus Neubauer, Medical Director for Professional Wellbeing at The US Oncology Network, to explore the pressing issue of provider burnout in healthcare. Together, they examine the root causes, personal and organizational impacts, and the importance of fostering a culture where provider well-being is not only supported, but expected. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, Dr. Mia Levy and Dr. Paul Conkling discuss new FDA-approved treatments and therapies for HR-positive, HER2-negative metastatic breast cancer. Discover innovative genomic testing techniques that are changing the identification of mutations, paving the way for more precise treatment strategies. Tune in as we spotlight advancements in personalized breast cancer care and learn about the advantages of liquid biopsy testing. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Tune into our debut episode of OncoTalks Case Journey as Dr. Paul Conkling and Dr. Mabel Mardones discuss two compelling cases of metastatic ER-positive breast cancer, emphasizing the role of antibody drug conjugates (ADCs) in treatment. They explore the challenges of HER2-low classification and the importance of early access to innovative therapies for improving patient outcomes. The conversation highlights the need for precise diagnostic approaches and the evolving landscape of breast cancer.  Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, Dr. Paul Conkling and Dr. David Cosgrove explore the latest advancements in mCRC treatment, highlighting the shift from traditional chemotherapy to innovative targeted therapies driven by genomic insights. We discuss the role of next-generation sequencing, new therapeutic agents, and clinical trials, while emphasizing personalized care, addressing treatment challenges, side effects, and financial considerations, offering a hopeful outlook on improved survival rates and future therapies with reduced toxicity. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Join us for the conclusion of our 2-part series on HER2-low breast cancer, featuring Dr. Paul Conkling and Dr. Erika Hamilton. They discuss the Phase 1 results from a HER2-low retrospective study evaluating HER2 testing patterns and concordant therapy in patients with HER2 metastatic breast cancer. Learn about the evolving role of HER2-low classification, ongoing education, and treatment strategies to enhance patient outcomes. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Join us as we explore the transformative potential of HER2 testing in breast cancer care. In this episode of OncoTalks, Dr. Paul Conkling and Dr. Erika Hamilton share cutting-edge insights that every oncologist should know to stay at the forefront of breast cancer treatment. Tune in to discover how HER2 testing is reshaping the landscape of personalized cancer therapy. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Join Dr. Robert Reid and Dr. Sreeni Chittoor as they explore the revolutionary impact of genomic testing in redefining cancer treatment. We focus on advanced solid tumors, such as non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, examining how these state-of-the-art technologies are leading to more personalized and effective treatment strategies. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Join Dr. Paul Conkling and Dr. Akash Mukherjee as they explore CAR-T Therapy from design of treatment through the patient journey. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Join Dr. Ira Zackon and Dr. David Andorsky on today’s episode of OncoTalks, as they discuss the expanding role of bispecific antibody therapies in the community for Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, Dr. David Waterhouse and Dr. Paul Conkling discuss NSCLC and the groundbreaking developments in treating patients with MET exon 14 (METex14) skipping mutations. We review the science behind these targeted therapies, their clinical applications, and the impact on patient outcomes. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode, Dr. David Waterhouse and Dr. Paul Conkling discuss the evolving landscape of second line treatments for extensive stage small cell lung cancer (SCLC). They review the latest research, promising therapies, and the impact of these treatments on patient quality of life. This episode offers vital information to help navigate treatment options and empower patients. Don’t miss this engaging discussion on a crucial topic in oncology, filled with expert insights! Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.